Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention

NCT04806633 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

UNKNOWN

Status

1722

Enrollment

OTHER

Sponsor class

Conditions

Left Cardiac Catheterization
Percutaneous Coronary Intervention
Acute Kidney Injury
Sodium-glucose Co-transporter 2 Inhibitors

Interventions

DRUG: Dapagliflozin 5mg
DRUG: Placebo

Sponsor

G.Gennimatas General Hospital

Collaborators

[object Object]